SPERMICIDAL AND VIRUCIDAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS
A method for inactivating spermatozoa, neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having spermicidal and/or antiviral properties produced by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as a spermicidal and/or antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an spermicidal and/or antiviral agent, and sophorolipid compounds for use as spermicidal and/or antiviral agents.
1 . A method for inactivating spermatozoa by treating the spermatozoa with an effective amount of a 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound.
2 . The method as claimed in claim 1 , wherein the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound is selected from the group consisting of:
17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;
Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;
Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and
combinations thereof.
3 . The method as claimed in claim 1 , wherein the sophorolipid compound is in the form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, a liquid imbibed in a sponge, and a liquid being released from an intravaginal or intrauterine delivery system.
4 . The method as claimed in claim 1 , further comprising combining the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound with a spermicidal agent.
5 . A method for neutralizing or inactivating a virus by treating the virus with an effective amount of a 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound.
6 . The method as claimed in claim 5 , wherein the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound is selected from the group consisting of:
17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;
Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;
Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and
combinations thereof.
7 . The method as claimed in claim 5 , wherein the sophorolipid compound is in the form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, a liquid imbibed in a sponge, and a liquid being released from an intravaginal or intrauterine delivery system.
8 . The method as claimed in claim 4 , further comprising combining the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound with an antiviral agent.
9 . A method for neutralizing or inactivating HIV by treating the HIV with an effective amount of a 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound.
10 . The method as claimed in claim 9 , wherein the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound is selected from the group consisting of:
17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate;
Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate;
Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and
combinations thereof.
11 . The method as claimed in claim 9 , wherein the sophorolipid compound is in the form selected from the group consisting of a gel, a film, a foam, a suppository, a pessary, a liposomic formulation, a liquid imbibed in a sponge, and a liquid being released from an intravaginal or intrauterine delivery system
12 . The method as claimed in claim 9 , further comprising combining the 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate sophorolipid compound with an antiviral agent.